Prevents nausea and vomiting. ANDA 78539, held by Aurobindo Pharma. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 78539 (Ondansetron Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Jul 31, 2007, with 7 approved supplements and 0 published complete response letters.
Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 31, 2007 | Original application | Approved | None posted |
| Ondansetron HydrochlorideEQ 4MG BASE · tablet;oral | Ondansetron Hydrochloride | Rx |
| Ondansetron HydrochlorideEQ 8MG BASE · tablet;oral | Ondansetron Hydrochloride | Rx |
| Ondansetron HydrochlorideEQ 24MG BASE · tablet;oral | Ondansetron Hydrochloride | Discontinued |
| Mar 2, 2026 | Supplement 16Labeling · Standard review | Approved | None posted |
| Mar 7, 2018 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 7, 2018 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 17, 2011 | Supplement 4Labeling | Approved | None posted |
| Jan 4, 2011 | Supplement 2Labeling | Approved | None posted |
| Jul 31, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters